Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VCEL | US
2.66
6.54%
Healthcare
Biotechnology
30/06/2024
04/10/2024
43.36
42.04
43.58
41.86
Vericel Corporation a commercial-stage biopharmaceutical company engages in the research development manufacture and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic and single or multiple full-thickness cartilage defects of the knee; and Epicel a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge Massachusetts.
View LessStrong Revenue Growth (> 10%)
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
51.6%1 month
47.5%3 months
46.6%6 months
42.2%4.32K
70.92
8.72
0.39
0.25
292.38
9.84
-
1.18M
2.17B
2.17B
-
-11.45
104.50
14.70
0.36
12.44
11.56
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
8.77
Range1M
10.36
Range3M
14.46
Rel. volume
0.75
Price X volume
12.55M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vera Therapeutics Inc. Class A Common Stock | VERA | Biotechnology | 40.84 | 2.35B | -2.18% | n/a | 16.11% |
Janux Therapeutics Inc. Common Stock | JANX | Biotechnology | 45.02 | 2.35B | 3.61% | n/a | 3.62% |
Arrowhead Pharmaceuticals Inc | ARWR | Biotechnology | 18.82 | 2.34B | -2.08% | n/a | 137.39% |
KEROS THERAPEUTICS INC. | KROS | Biotechnology | 60.9 | 2.30B | -0.67% | n/a | 3.32% |
Novavax Inc | NVAX | Biotechnology | 13.61 | 2.18B | -7.29% | n/a | -54.03% |
Centessa Pharmaceuticals plc American Depositary Shares | CNTA | Biotechnology | 15.94 | 2.05B | -1.97% | n/a | 29.85% |
Akero Therapeutics Inc | AKRO | Biotechnology | 28.24 | 2.04B | -3.32% | n/a | 4.54% |
Celldex Therapeutics Inc | CLDX | Biotechnology | 30.65 | 2.03B | 1.46% | n/a | 0.29% |
Harmony Biosciences Holdings Inc. | HRMY | Biotechnology | 34.6 | 2.00B | -2.73% | 20.07 | 40.71% |
Maravai LifeSciences Holdings Inc | MRVI | Biotechnology | 7.89 | 1.99B | -0.13% | n/a | 128.60% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 292.38 | 0.76 | Expensive |
Ent. to Revenue | 9.84 | 3,674.48 | Cheaper |
PE Ratio | 4,319.00 | 38.01 | Expensive |
Price to Book | 8.72 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 46.60 | 74.67 | Lower Risk |
Debt to Equity | 0.39 | -1.82 | Expensive |
Debt to Assets | 0.25 | 0.26 | Par |
Market Cap | 2.17B | 3.73B | Emerging |